MedTrace Logo

Treating Adolescent Obsessive Compulsive Disorder With Transcranial Magnetic Stimulation

NCT07065669 · Status: RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 30

Last updated 2025-07-15

No results posted yet for this study

Summary

This is a pilot study to examine the tolerability, safety and early efficacy of two forms of transcranial magnetic stimulation (TMS) for treating adolescents with Obsessive Compulsive Disorder (OCD) who have experienced limited improvements with usual treatments for OCD in adolescents.

The project's primary goal is to examine whether adolescents can complete 3 consecutive weeks of TMS administered 5 days per week, and to describe the type of and how common individual side effects with TMS occur in adolescents with OCD.

Participants will:

* visit the clinic every weekday for 3 weeks (15 days) to receive TMS treatments
* have a brain MRI scan before TMS treatments begins and after finishing all TMS
* complete questionnaires and report changes in behavior and physical symptoms

Conditions

  • Obsessive-Compulsive Disorder

Interventions

DEVICE

Dorsal medial Prefrontal Cortex intermittent theta burst stimulation

iTBS stimulation of the dmPFC is a FDA-approved treatment for adults with OCD

DEVICE

cTBS to ROFC

continuous theta burst stimulation (cTBS) 1,800 pulses per session

Sponsors & Collaborators

Principal Investigators

  • James T McCracken, MD · University of California, San Francisco

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
13 Years
Max Age
17 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-06-01
Primary Completion
2027-07-01
Completion
2027-07-01
FDA Device
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07065669 on ClinicalTrials.gov